Author

P. Schommers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Assay:proteomics· 5 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Research Focus:differential expression· 2

Frequent Co-Authors

F. Klein· 7 shared H. Gruell· 5 shared L. Gieselmann· 5 shared C. Kreer· 4 shared M. S. Ercanoglu· 4 shared K. Vanshylla· 3 shared N. Pfeifer· 3 shared H. Janicki· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

F. Klein

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning

C. E. Radford, P. Schommers, L. Gieselmann, K. H. Crawford, B. Dadonaite, T. C. Yu, A. S. Dingens, J. Overbaugh, F. Klein, J. D. Bloom

This study maps the neutralizing specificity of human anti-HIV serum using deep mutational scanning to identify Env mutations affecting neutralization by polyclonal sera.

bioRxiv · Mar 23, 2023Immunology

Probabilities of HIV-1 bNAb development in healthy and chronically infected individuals

C. Kreer, C. Lupo, M. S. Ercanoglu, L. Gieselmann, N. Spisak, J. Grossbach, M. Schlotz, P. Schommers, H. Gruell, L. Dold, A. Beyer, A. Nourmohammad, T. Mora, A. Walczak, F. Klein

The paper uses sequence analysis to predict the likelihood of HIV-1 broadly neutralizing antibody (bNAb) development in healthy and infected individuals, finding that chronic infection is not required for bNAb generation.

bioRxiv · Jul 11, 2022Immunology

Delineating antibody escape from Omicron sublineages

H. Gruell, K. Vanshylla, M. Korenkov, P. Tober-Lau, M. Zehner, F. Muenn, H. Janicki, M. Augustin, P. Schommers, L. E. Sander, F. Kurth, C. Kreer, F. Klein

This study evaluates antibody escape from Omicron sublineages by testing serum and monoclonal antibody activity against BA.1, BA.2, BA.2.12.1, and BA.4/5, revealing increased resistance in BA.4/5 and identifying promising neutralizing antibodies.

bioRxiv · Apr 6, 2022 · PreprintImmunology

A naturally arising broad and potent CD4-binding site antibody with low somatic mutation

C. O. Barnes, T. Schoofs, P. N. P. Gnanapragasam, J. Golijanin, K. E. Huey-Tubman, H. Gruell, P. Schommers, N. Suh-Toma, Y. E. Lee, J. C. C. Lorenzi, A. Piechocka-Trocha, J. F. Scheid, A. P. West, B. D. Walker, M. S. Seaman, , P. J. Bjorkman

This paper describes a VRC01-class antibody with lower somatic mutation but comparable breadth and potency to other broadly neutralizing antibodies against HIV-1.

bioRxiv · Mar 16, 2022Immunology

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2

K. Vanshylla, V. Di Cristianziano, F. Kleipass, F. Dewald, P. Schommers, L. Gieselmann, H. Gruell, M. Schlotz, M. S. Ercanoglu, R. Stumpf, P. Mayer, E. Heger, W. Johannis, C. Horn, I. Suarez, , F. Klein

This study examines the kinetics and correlates of the SARS-CoV-2 neutralizing antibody response in 963 recovered individuals over 10 months, finding variations in antibody persistence and identifying factors predicting neutralizing activity.

bioRxiv · Jan 26, 2021 · PreprintImmunology

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

C. Kreer, M. Zehner, T. Weber, C. Rohde, S. Halwe, M. S. Ercanoglu, L. Gieselmann, M. Korenkov, H. Gruell, P. Schommers, K. Vanshylla, V. Di Cristanziano, H. Janicki, R. Brinker, A. Ashurov, , F. Klein

This study isolates potent SARS-CoV-2-neutralizing antibodies from COVID-19 patients as early as 8 days post-diagnosis and identifies precursor B cells in healthy individuals.

bioRxiv · Jun 12, 2020Immunology

openPrimeR for multiplex amplification of highly diverse templates

C. Kreer, M. Doering, N. Lehnen, M. S. Ercanoglu, L. Gieselmann, D. Luca, K. Jain, P. Schommers, N. Pfeifer, F. Klein

The paper introduces openPrimeR, an R-based tool for designing multiplex PCR primers for highly diverse templates, and demonstrates its effectiveness in amplifying immunoglobulins.

bioRxiv · Nov 20, 2019Immunology